Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) completed its entry into the public markets in December 2018 through a business combination with Avista Healthcare Public Acquisition Corp, a blank-check company sponsored by healthcare-focused private equity firm Avista Capital Partners. The transaction, reflected in an 8-K filing dated December 10, 2018, transferred the regenerative medicine and wound care company to public markets under the ORGO ticker on Nasdaq. Organogenesis develops and commercializes products in advanced wound care and surgical biologics, and the deal marked the conclusion of the SPAC's search for a healthcare-sector target. The company has since remained actively listed. Sign up for SpacDesk to access full filing data, sponsor profiles, and deal analytics on ORGO and hundreds of other SPAC transactions.